Patents by Inventor Katrien LUYTEN

Katrien LUYTEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENTS OF PROSTATE CANCER WITH COMBINATIONS OF ABIRATERONE ACETATE AND NIRAPARIB
    Publication number: 20230226080
    Abstract: The present disclosure relates to a combination of abiraterone acetate and niraparib, free-dose and fixed-dose combinations of abiraterone acetate and niraparib, and methods of treatment of prostate cancer with said combinations.
    Type: Application
    Filed: May 7, 2021
    Publication date: July 20, 2023
    Inventors: Thomas Ronald A. QUINTEN, Urbain Alfons C. DELAET, Philip Erna H. HEYNS, Tatiana MARCOZZI, Johny BERTELS, Katrien LUYTEN, Kaustubh Ramesh TAMBWEKAR, Angela LOPEZ-GITLITZ, Paul J. A. HARTMAN KOK
  • PHARMACEUTICAL FORMULATIONS OF ABIRATERONE ACETATE AND NIRAPARIB
    Publication number: 20230226081
    Abstract: The present disclosure relates to a combination of abiraterone acetate and niraparib, free-dose and fixed-dose combinations of abiraterone acetate and niraparib, and methods of treatment of prostate cancer with said combinations.
    Type: Application
    Filed: May 7, 2021
    Publication date: July 20, 2023
    Inventors: Thomas Ronald A. QUINTEN, Urbain Alfons C. DELAET, Philip Erna H. HEYNS, Tatiana MARCOZZI, Johny BERTELS, Katrien LUYTEN, Kaustubh Ramesh TAMBWEKAR, Angela LOPEZ-GITLITZ, Paul J. A. HARTMAN KOK
  • TREATMENT OF PROSTATE CANCER WITH A COMBINATION OF ABIRATERONE ACETATE AND NIRAPARIB
    Publication number: 20230218640
    Abstract: The present disclosure relates to a combination of abiraterone acetate and niraparib, free-dose and fixed-dose combinations of abiraterone acetate and niraparib, and methods of treatment of prostate cancer with said combinations.
    Type: Application
    Filed: May 7, 2021
    Publication date: July 13, 2023
    Inventors: Thomas Ronald A. QUINTEN, Urbain Alfons C. DELAET, Philip Erna H. HEYNS, Tatiana MARCOZZI, Johny BERTELS, Katrien LUYTEN, Kaustubh Ramesh TAMBWEKAR, Angela LOPEZ-GITLITZ, Paul J. A. HARTMAN KOK
  • CONTROLLED RELEASE SELEXIPAG COMPOSITION
    Publication number: 20230113077
    Abstract: The present invention is concerned with controlled release compositions for oral administration comprising 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N- isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide (selexipag, NS-304, ACT- 293987) and its pharmaceutically acceptable salts and/or 2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetic acid (metabolite of selexipag, MRE-269, ACT- 333679) and its pharmaceutically acceptable salts; and with processes for preparing such controlled release compositions as well as to uses thereof.
    Type: Application
    Filed: January 29, 2021
    Publication date: April 13, 2023
    Inventors: Katrien LUYTEN, Annelien VAN DROOGENBROECK